Paving the way of systems biology and precision medicine in allergic diseases: the MeDALL success story: Mechanisms of the Development of ALLergy; EU FP7-CP-IP; Project No: 261357; 2010-2015.
Paving the way of systems biology and precision medicine in allergic diseases: the MeDALL success story: Mechanisms of the Development of ALLergy; EU FP7-CP-IP; Project No: 261357; 2010-2015.
复制标题
在过敏性疾病中铺平系统生物学和精确医学的方式：奖章的成功故事：过敏的发展机制；欧盟FP7-CP-IP;项目编号：261357； 2010-2015。
作者：
Bousquet J;Anto JM;Akdis M;Auffray C;Keil T;Momas I;Postma DS;Valenta R;Wickman M;Cambon-Thomsen A;Haahtela T;Lambrecht BN;Lodrup Carlsen KC;Koppelman GH;Sunyer J;Zuberbier T;Annesi-Maesano I;Arno A;Bindslev-Jensen C;De Carlo G;Forastiere F;Heinrich J;Kowalski ML;Maier D;Melén E;Palkonen S;Smit HA;Standl M;Wright J;Asarnoj A;Benet M;Ballardini N;Garcia-Aymerich J;Gehring U;Guerra S;Hohman C;Kull I;Lupinek C;Pinart M;Skrindo I;Westman M;Smagghe D;Akdis C;Albang R;Anastasova V;Anderson N;Bachert C;Ballereau S;Ballester F;Basagana X;Bedbrook A;Bergstrom A;von Berg A;Brunekreef B;Burte E;Carlsen KH;Chatzi L;Coquet JM;Curin M;Demoly P;Eller E;Fantini MP;Gerhard B;Hammad H;von Hertzen L;Hovland V;Jacquemin B;Just J;Keller T;Kerkhof M;Kiss R;Kogevinas M;Koletzko S;Lau S;Lehmann I;Lemonnier N;McEachan R;Mäkelä M;Mestres J;Minina E;Mowinckel P;Nadif R;Nawijn M;Oddie S;Pellet J;Pin I;Porta D;Rancière F;Rial-Sebbag A;Saeys Y;Schuijs MJ;Siroux V;Tischer CG;Torrent M;Varraso R;De Vocht J;Wenger K;Wieser S;Xu C
MeDALL （mechanism of Development of ALLergy, EU FP7‐CP‐IP，项目编号：261357,2010-2015）提出了一种创新的方法来开发用于预测、诊断、预防和治疗目标的早期指标。MeDALL采用逐步、大规模和综合的方法将流行病学、临床和基础研究联系起来：将欧洲14个出生队列中精确表型儿童的MeDALL数据与系统生物学（组学、使用微阵列进行IgE测量）和环境数据相结合。同一儿童的多重发病比预期的仅仅是偶然的更常见，这表明这些疾病具有共同的因果机制，而不管IgE是否致敏。在单致敏和多致敏个体中，应区别考虑IgE致敏。过敏性多病和IgE多致敏通常与过敏性疾病的持续或严重程度有关。环境暴露与过敏相关疾病的发生有关。为了补充以人群为基础的儿童研究，MeDALL纳入了机械实验动物研究和人类体外研究。多发病和多致敏的整合形成了一种新的变态反应性疾病分类框架，有助于提高对变态反应的遗传和表观遗传机制的理解，并有助于更好地管理变态反应性疾病。考虑了道德和性别问题。MeDALL已在欧盟议程内部署了翻译活动。
MeDALL (Mechanisms of the Development of ALLergy; EU FP7‐CP‐IP; Project No: 261357; 2010–2015) has proposed an innovative approach to develop early indicators for the prediction, diagnosis, prevention and targets for therapy. MeDALL has linked epidemiological, clinical and basic research using a stepwise, large‐scale and integrative approach: MeDALL data of precisely phenotyped children followed in 14 birth cohorts spread across Europe were combined with systems biology (omics, IgE measurement using microarrays) and environmental data. Multimorbidity in the same child is more common than expected by chance alone, suggesting that these diseases share causal mechanisms irrespective of IgE sensitization. IgE sensitization should be considered differently in monosensitized and polysensitized individuals. Allergic multimorbidities and IgE polysensitization are often associated with the persistence or severity of allergic diseases. Environmental exposures are relevant for the development of allergy‐related diseases. To complement the population‐based studies in children, MeDALL included mechanistic experimental animal studies and in vitro studies in humans. The integration of multimorbidities and polysensitization has resulted in a new classification framework of allergic diseases that could help to improve the understanding of genetic and epigenetic mechanisms of allergy as well as to better manage allergic diseases. Ethics and gender were considered. MeDALL has deployed translational activities within the EU agenda.